Nanodelivery of oxiracetam enhances memory, functional recovery and induces neuroprotection following concussive head injury.

Blood-brain barrier Brain edema Brain pathology Concussive head injury Functional deficit Neuroprotection Oxiracetam TiO2 nanowired delivery

Journal

Progress in brain research
ISSN: 1875-7855
Titre abrégé: Prog Brain Res
Pays: Netherlands
ID NLM: 0376441

Informations de publication

Date de publication:
2021
Historique:
entrez: 25 9 2021
pubmed: 26 9 2021
medline: 25 11 2021
Statut: ppublish

Résumé

Military personnel are the most susceptible to concussive head injury (CHI) caused by explosion, blast or missile or blunt head trauma. Mild to moderate CHI could induce lifetime functional and cognitive disturbances causing significant decrease in quality of life. Severe CHI leads to instant death and lifetime paralysis. Thus, further exploration of novel therapeutic agents or new features of known pharmacological agents are needed to enhance quality of life of CHI victims. Previous reports from our laboratory showed that mild CHI induced by weight drop technique causing an impact of 0.224N results in profound progressive functional deficit, memory impairment and brain pathology from 5h after trauma that continued over several weeks of injury. In this investigation we report that TiO2 nanowired delivery of oxiracetam (50mg/kg, i.p.) daily for 5 days after CHI resulted in significant improvement of functional deficit on the 8th day. This was observed using Rota Rod treadmill, memory improvement assessed by the time spent in finding hidden platform under water. The motor function improvement is seen in oxiracetam treated CHI group by placing forepaw on an inclined mesh walking and foot print analysis for stride length and distance between hind feet. TiO2-nanowired oxiracetam also induced marked improvements in the cerebral blood flow, reduction in the BBB breakdown and edema formation as well as neuroprotection of neuronal, glial and myelin damages caused by CHI at light and electron microscopy on the 7th day after 5 days TiO2 oxiracetam treatment. Adverse biochemical events such as upregulation of CSF nitrite and nitrate, IL-6, TNF-a and p-Tau are also reduced significantly in oxiracetam treated CHI group. On the other hand post treatment of 100mg/kg dose of normal oxiracetam in identical conditions after CHI is needed to show slight but significant neuroprotection together with mild recovery of memory function and functional deficits on the 8th day. These observations are the first to point out that nanowired delivery of oxiracetam has superior neuroprotective ability in CHI. These results indicate a promising clinical future of TiO2 oxiracetam in treating CHI patients for better quality of life and neurorehabilitation, not reported earlier.

Identifiants

pubmed: 34560921
pii: S0079-6123(21)00150-3
doi: 10.1016/bs.pbr.2021.06.004
pii:
doi:

Substances chimiques

Neuroprotective Agents 0
Pyrrolidines 0
oxiracetam P7U817352G

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

139-230

Subventions

Organisme : NIA NIH HHS
ID : R01 AG028679
Pays : United States

Informations de copyright

Copyright © 2021 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Conflict of interest There is no conflict of interest between any entity and/or organization mentioned here.

Auteurs

Feng Niu (F)

CSPC NBP Pharmaceutical Medicine, Shijiazhuang, China.

Aruna Sharma (A)

International Experimental Central Nervous System Injury & Repair (IECNSIR), Department of Surgical Sciences, Anesthesiology & Intensive Care Medicine, Uppsala University Hospital, Uppsala University, Uppsala, Sweden. Electronic address: aruna.sharma@surgsci.uu.se.

Zhenguo Wang (Z)

CSPC NBP Pharmaceutical Medicine, Shijiazhuang, China.

Lianyuan Feng (L)

Department of Neurology, Bethune International Peace Hospital, Shijiazhuang, China.

Dafin F Muresanu (DF)

Department of Clinical Neurosciences, University of Medicine & Pharmacy, Cluj-Napoca, Romania; "RoNeuro" Institute for Neurological Research and Diagnostic, Cluj-Napoca, Romania.

Seaab Sahib (S)

Department of Chemistry & Biochemistry, University of Arkansas, Fayetteville, AR, United States.

Z Ryan Tian (ZR)

Department of Chemistry & Biochemistry, University of Arkansas, Fayetteville, AR, United States.

José Vicente Lafuente (JV)

LaNCE, Department of Neuroscience, University of the Basque Country (UPV/EHU), Leioa, Bizkaia, Spain.

Anca D Buzoianu (AD)

Department of Clinical Pharmacology and Toxicology, "Iuliu Hatieganu" University of Medicine and Pharmacy, Cluj-Napoca, Romania.

Rudy J Castellani (RJ)

Department of Pathology, University of Maryland, Baltimore, MD, United States.

Ala Nozari (A)

Anesthesiology & Intensive Care, Massachusetts General Hospital, Boston, MA, United States.

Preeti K Menon (PK)

Department of Biochemistry and Biophysics, Stockholm University, Stockholm, Sweden.

Ranjana Patnaik (R)

Department of Biomaterials, School of Biomedical Engineering, Indian Institute of Technology, Banaras Hindu University, Varanasi, India.

Lars Wiklund (L)

International Experimental Central Nervous System Injury & Repair (IECNSIR), Department of Surgical Sciences, Anesthesiology & Intensive Care Medicine, Uppsala University Hospital, Uppsala University, Uppsala, Sweden.

Hari Shanker Sharma (HS)

International Experimental Central Nervous System Injury & Repair (IECNSIR), Department of Surgical Sciences, Anesthesiology & Intensive Care Medicine, Uppsala University Hospital, Uppsala University, Uppsala, Sweden. Electronic address: sharma@surgsci.uu.se.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH